India Covid Vaccine Compensation Policy
Analysis based on 7 articles · First reported Mar 10, 2026 · Last updated Mar 10, 2026
The directive for a no-fault compensation policy by the India — Supreme Court of India could lead to increased financial outlays for the India, potentially impacting public health budgets. For pharmaceutical companies like those involved with Oxford–AstraZeneca COVID-19 vaccine, it clarifies that the policy is not an admission of liability, which could mitigate direct legal risks but may still influence public perception of vaccine safety.
The India — Supreme Court of India has directed the India to establish a no-fault compensation policy for individuals who experience serious adverse events following Covid-19 vaccination. This decision, delivered by a bench including Justices Vikram Nath and Sandeep Mehta, comes in response to pleas, including one alleging two women died after receiving the Oxford–AstraZeneca COVID-19 vaccine vaccine. The court clarified that the existing mechanism for monitoring adverse events will continue, and no separate expert body is deemed necessary. Furthermore, the formulation of this framework will not be interpreted as an admission of liability by the India or any other authority, and individuals retain the right to pursue other legal remedies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard